Clin Microbiol Infect. 2011 Jan 17. doi: 10.1111/j.1469-0691.2011.03459.x.
High sensitivity and specificity of the C6-peptide ELISA on cerebrospinal fluid in Lyme neuroborreliosis patients.
Department of Medical Microbiology, Centre of Infectious Diseases, Leiden University Medical Centre, Leiden ) IZORE, Centre for Infectious Diseases, Leeuwarden ) Department of Medical Microbiology, OLVG, Amsterdam, The Netherlands.
Clin Microbiol Infect ABSTRACT:
Lyme neuroborreliosis (LNB) is a serious but treatable disease.
The diagnosis of LNB poses a challenge to clinicians, and improved tests are needed.
The C6-peptide ELISA is frequently used on serum but not on cerebrospinal fluid (CSF).
Data on the sensitivity of the C6-peptide ELISA in CSF in patients suffering from LNB have been conflicting.
Serum-CSF pairs from 59 LNB patients, 36 Lyme non-neuroborreliosis cases, 69 infectious meningitis/encephalitis controls and 74 neurological controls were tested in a C6-peptide ELISA.
With the optimal cut-off of 1.1, the sensitivity of the C6-peptide ELISA for LNB patients in CSF was 95%, and the specificity was 83% in the Lyme non-neuroborreliosis patients, 96% in the infectious controls, and 97% in the neurological controls.
These results suggest that the C6-peptide ELISA has a high sensitivity and good specificity for the diagnosis of LNB patients in CSF.
The C6-peptide ELISA can be used on CSF in a clinical setting to screen for LNB.
PMID: 21375653 [PubMed - as supplied by publisher]